(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Artelo Biosciences, Bionano Genomics, and BioCardia.

The three biggest losers today are Brilliant Acquisition Corporation, Zscaler, and Applied Molecular Transport.

Winners today

1. Artelo Biosciences (ARTLW) – 57.23%

NASDAQ ended the session with Artelo Biosciences rising 57.23% to $0.05 on Friday while NASDAQ rose 2.05% to $11,697.80.

More news about Artelo Biosciences.

2. Bionano Genomics (BNGOW) – 21.6%

NASDAQ ended the session with Bionano Genomics rising 21.6% to $0.18 on Friday while NASDAQ rose 2.05% to $11,697.80.

Yearly Top and Bottom Value

Bionano Genomics’s stock is valued at $0.18 at 16:32 EST, below its 52-week high of $0.18 and above its 52-week low of $0.18.

More news about Bionano Genomics.

3. BioCardia (BCDAW) – 19.33%

NASDAQ ended the session with BioCardia rising 19.33% to $1.42 on Friday while NASDAQ rose 2.05% to $11,697.80.

Yearly Top and Bottom Value

BioCardia’s stock is valued at $1.42 at 16:32 EST, way above its 52-week high of $1.05.

More news about BioCardia.

4. Zai Lab (ZLAB) – 12.46%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab rising 12.46% to $41.53 on Friday, following the last session’s downward trend. NASDAQ rose 2.05% to $11,697.80, following the last session’s upward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-3.46.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.05%.

More news about Zai Lab.

5. Burning Rock Biotech Limited (BNR) – 12.37%

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.

NASDAQ ended the session with Burning Rock Biotech Limited rising 12.37% to $3.27 on Friday, following the last session’s upward trend. NASDAQ rose 2.05% to $11,697.80, following the last session’s upward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, Burning Rock Biotech Limited has a trailing twelve months EPS of $-1.059.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.89%.

More news about Burning Rock Biotech Limited.

6. Novavax (NVAX) – 11.18%

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax jumping 11.18% to $7.70 on Friday, following the last session’s upward trend. NASDAQ jumped 2.05% to $11,697.80, following the last session’s upward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Novavax has a trailing twelve months EPS of $-7.27.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 90% and a drop 158.6% for the next.

More news about Novavax.

7. Cabaletta Bio (CABA) – 10.69%

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

NASDAQ ended the session with Cabaletta Bio jumping 10.69% to $9.01 on Friday while NASDAQ jumped 2.05% to $11,697.80.

Earnings Per Share

As for profitability, Cabaletta Bio has a trailing twelve months EPS of $-1.64.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -50.54%.

Yearly Top and Bottom Value

Cabaletta Bio’s stock is valued at $9.01 at 16:32 EST, way under its 52-week high of $12.88 and way above its 52-week low of $0.59.

Moving Average

Cabaletta Bio’s value is under its 50-day moving average of $9.76 and way above its 200-day moving average of $3.80.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 8.2% and 4.4%, respectively.

More news about Cabaletta Bio.

8. Fastly (FSLY) – 10.46%

Fastly, Inc. operates an edge cloud platform for processing, serving, and securing its customer's applications in the United States, the Asia Pacific, Europe, and internationally. The edge cloud is a category of Infrastructure as a Service that enables developers to build, secure, and deliver digital experiences at the edge of the internet. It is a programmable platform designed for web and application delivery. The company offers Compute@Edge; developer hub that includes solution library patterns and recipes, API and language references, change logs, and Fastly Fiddle solutions; device detection and geolocation, edge dictionaries, edge access control lists, and edge authentication services; full site delivery services, such as dynamic site acceleration, origin shield, instant purge, surrogate keys, real-time logging and stats, cloud optimizer, programmatic control, edge databases, content compression, reliability, and modern protocols and performance services; and streaming solutions and services, including live streaming, media shield, and origin connect. It also provides edge security solutions, such as DDoS protection and cloud, edge web application firewall (WAF), transport layer security (TLS), platform TLS, and compliance services; unified web application and API protection solutions that includes runtime self-application protection, advanced rate limiting, API and ATO protection, account takeover protection, bot protection, and next generation WAF. In addition, the company offers edge applications, such as load balancers and image optimizers; video on demand; and managed edge delivery services. It serves customers operating in digital publishing, media and entertainment, technology, online retail, travel and hospitality, and financial services industries. The company was formerly known as SkyCache, Inc. and changed its name to Fastly, Inc. in May 2012. Fastly, Inc. was incorporated in 2011 and is headquartered in San Francisco, California.

NYSE ended the session with Fastly jumping 10.46% to $14.94 on Friday while NYSE rose 1.17% to $15,705.46.

Earnings Per Share

As for profitability, Fastly has a trailing twelve months EPS of $-0.93.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.46%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 13.3% and a negative 27.3%, respectively.

Volatility

Fastly’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.98%, a positive 1.67%, and a positive 4.22%.

Fastly’s highest amplitude of average volatility was 3.59% (last week), 6.36% (last month), and 4.22% (last quarter).

More news about Fastly.

9. Berkeley Lights (BLI) – 9.88%

Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. The company was incorporated in 2011 and is headquartered in Emeryville, California.

NASDAQ ended the session with Berkeley Lights jumping 9.88% to $1.78 on Friday while NASDAQ rose 2.05% to $11,697.80.

Earnings Per Share

As for profitability, Berkeley Lights has a trailing twelve months EPS of $-1.54.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -55.98%.

Moving Average

Berkeley Lights’s worth is way under its 50-day moving average of $2.21 and way below its 200-day moving average of $3.40.

More news about Berkeley Lights.

10. BioSig Technologies (BSGM) – 9.24%

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

NASDAQ ended the session with BioSig Technologies jumping 9.24% to $1.12 on Friday while NASDAQ jumped 2.05% to $11,697.80.

Earnings Per Share

As for profitability, BioSig Technologies has a trailing twelve months EPS of $-1.872.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -283.86%.

More news about BioSig Technologies.

Losers Today

1. Brilliant Acquisition Corporation (BRLIW) – -48.16%

NASDAQ ended the session with Brilliant Acquisition Corporation dropping 48.16% to $0.03 on Friday, after five successive sessions in a row of losses. NASDAQ rose 2.05% to $11,697.80, following the last session’s upward trend on what was an all-around bullish trend trading session today.

More news about Brilliant Acquisition Corporation.

2. Zscaler (ZS) – -10.86%

Zscaler, Inc. operates as a cloud security company worldwide. It offers Zscaler Internet Access solution that provides users, workloads, IoT, and OT devices secure access to externally managed applications, including software-as-a-service (SaaS) applications and internet destinations; and Zscaler Private Access solution, which is designed to provide access to managed applications hosted internally in data centers, and private or public clouds. The company also provides Zscaler Digital Experience that measures end-to-end user experience across business applications, as well as provides an easy to understand digital experience score for each user, application, and location within an enterprise. In addition, it offers Posture Control solutions comprising Cloud Security Posture Management that identifies and remediates application misconfigurations in SaaS, infrastructure as a service, and PaaS to reduce risk and ensure compliance with industry and organizational benchmarks; Cloud Infrastructure Entitlement Management that detects and remediates excessive or unused cloud permissions and enforces least privileged access without disrupting productivity; Infrastructure as Code (IaC), which analyzes IaC templates to identify misconfigurations and other security issues prior to deployment to cloud infrastructure; and Vulnerability Scanning and Data Loss Prevention solutions. The company's platform modules include Zscaler Central Authority, Zscaler Enforcement Node, and Zscaler Log Servers. It serves customers in airlines and transportation, conglomerates, consumer goods and retail, financial services, healthcare, manufacturing, media and communications, public sector and education, technology, and telecommunications services industries. The company was formerly known as SafeChannel, Inc., and changed its name to Zscaler, Inc. in August 2008. Zscaler, Inc. was incorporated in 2007 and is headquartered in San Jose, California.

NASDAQ ended the session with Zscaler sliding 10.86% to $119.57 on Friday while NASDAQ rose 2.05% to $11,697.80.

Earnings Per Share

As for profitability, Zscaler has a trailing twelve months EPS of $-1.45.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -76.47%.

Volume

Today’s last reported volume for Zscaler is 11180300 which is 359.12% above its average volume of 2435100.

Sales Growth

Zscaler’s sales growth is 42.7% for the ongoing quarter and 35.1% for the next.

Previous days news about Zscaler

• Zscaler (zs) Q2 earnings and revenues surpass estimates. According to Zacks on Thursday, 2 March, "While Zscaler has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"

More news about Zscaler.

3. Applied Molecular Transport (AMTI) – -9.98%

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Applied Molecular Transport dropping 9.98% to $0.56 on Friday, following the last session’s downward trend. NASDAQ jumped 2.05% to $11,697.80, following the last session’s upward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Applied Molecular Transport has a trailing twelve months EPS of $-2.82.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -100.73%.

Moving Average

Applied Molecular Transport’s worth is below its 50-day moving average of $0.60 and way under its 200-day moving average of $1.56.

More news about Applied Molecular Transport.

4. BOQI International Medical (BIMI) – -7.14%

BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. It offers prescription and over-the-counter drugs, nutritional supplements, health foods, and sundry products, as well as traditional Chinese medicines, personal and family care products, and miscellaneous items under the Lijiantang Pharmacy brand name. The company also provides IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BOQI International Medical Inc. and changed its name to BIMI International Medical Inc. in June 2021. BIMI International Medical Inc. was incorporated in 2000 and is based in Dalian, the People's Republic of China.

NASDAQ ended the session with BOQI International Medical dropping 7.14% to $1.04 on Friday while NASDAQ rose 2.05% to $11,697.80.

Earnings Per Share

As for profitability, BOQI International Medical has a trailing twelve months EPS of $-61.91.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -178.88%.

Moving Average

BOQI International Medical’s value is way under its 50-day moving average of $1.44 and way below its 200-day moving average of $3.50.

Yearly Top and Bottom Value

BOQI International Medical’s stock is valued at $1.04 at 16:32 EST, way under its 52-week high of $16.70 and above its 52-week low of $1.01.

More news about BOQI International Medical.

5. Brooge Energy Limited (BROG) – -5.42%

Brooge Energy Limited, through its subsidiaries, provides oil storage and related services at the Port of Fujairah in the emirate of Fujairah in the United Arab Emirates. The company operates phase I facility that comprises 14 storage tanks with an aggregate geometric capacity of 399,324 cbm for the storage, heating, and blending of fuel oil and clean petroleum products, including aviation fuel, gas oil, gasoline, marine gas oil, and naphtha. It also provides ancillary services, which comprise blending and circulation, heating, throughput, and intertank transfer. The company was formerly known as Brooge Holdings Limited and changed its name to Brooge Energy Limited in April 2020. Brooge Energy Limited is headquartered in Fujairah, the United Arab Emirates.

NASDAQ ended the session with Brooge Energy Limited falling 5.42% to $5.58 on Friday, after five consecutive sessions in a row of losses. NASDAQ jumped 2.05% to $11,697.80, following the last session’s upward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Brooge Energy Limited has a trailing twelve months EPS of $0.13.

PE Ratio

Brooge Energy Limited has a trailing twelve months price to earnings ratio of 42.92. Meaning, the purchaser of the share is investing $42.92 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.1%.

Yearly Top and Bottom Value

Brooge Energy Limited ‘s stock is valued at $5.58 at 16:32 EST, way below its 52-week high of $9.80 and way higher than its 52-week low of $4.90.

Moving Average

Brooge Energy Limited ‘s value is under its 50-day moving average of $5.83 and way under its 200-day moving average of $7.13.

More news about Brooge Energy Limited .

6. American Resources Corporation (AREC) – -5.39%

American Resources Corporation supplies raw materials for the global infrastructure marketplace. The company offers metallurgical coal and coal used in pulverized coal injection that are essential building blocks in the steel manufacturing process. It has a portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia. The company was founded in 2006 and is headquartered in Fishers, Indiana.

NASDAQ ended the session with American Resources Corporation sliding 5.39% to $1.58 on Friday, following the last session’s downward trend. NASDAQ jumped 2.05% to $11,697.80, following the last session’s upward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, American Resources Corporation has a trailing twelve months EPS of $-0.349.

More news about American Resources Corporation.

7. Arcutis Biotherapeutics (ARQT) – -5.21%

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

NASDAQ ended the session with Arcutis Biotherapeutics dropping 5.21% to $15.82 on Friday while NASDAQ jumped 2.05% to $11,697.80.

Earnings Per Share

As for profitability, Arcutis Biotherapeutics has a trailing twelve months EPS of $-3.55.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -98.07%.

Volume

Today’s last reported volume for Arcutis Biotherapeutics is 1097790 which is 35.71% above its average volume of 808905.

More news about Arcutis Biotherapeutics.

8. Brookfield Residential Properties (BRP) – -5.2%

BRP Group, Inc. markets and sells insurance products and services in the United States. The company operates through four segments: Middle Market, Specialty, MainStreet, and Medicare. The Middle Market segment provides private risk management, commercial risk management, and employee benefits solutions for mid-to-large size businesses, and high net worth individuals and families. The Specialty segment operates as a wholesale co-brokerage platform that delivers programs requiring underwriting and placement services. The MainStreet segment offers personal insurance, commercial insurance, and life and health solutions to individuals and businesses in their communities. The Medicare segment provides consultation for government assistance programs and solutions to seniors and individuals through a network of agents. The company was founded in 2011 and is headquartered in Tampa, Florida.

NASDAQ ended the session with Brookfield Residential Properties falling 5.2% to $26.41 on Friday, following the last session’s upward trend. NASDAQ rose 2.05% to $11,697.80, following the last session’s upward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Brookfield Residential Properties has a trailing twelve months EPS of $-0.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.59%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 10% and positive 17.4% for the next.

Sales Growth

Brookfield Residential Properties’s sales growth is 27.3% for the present quarter and 22.8% for the next.

Moving Average

Brookfield Residential Properties’s worth is under its 50-day moving average of $28.73 and below its 200-day moving average of $27.76.

Yearly Top and Bottom Value

Brookfield Residential Properties’s stock is valued at $26.41 at 16:32 EST, way under its 52-week high of $33.34 and way above its 52-week low of $17.08.

More news about Brookfield Residential Properties.

9. Brilliant Acquisition Corporation (BRLIR) – -5.05%

NASDAQ ended the session with Brilliant Acquisition Corporation dropping 5.05% to $0.19 on Friday, after five successive sessions in a row of losses. NASDAQ rose 2.05% to $11,697.80, following the last session’s upward trend on what was an all-around up trend trading session today.

Yearly Top and Bottom Value

Brilliant Acquisition Corporation’s stock is valued at $0.19 at 16:32 EST, above its 52-week high of $0.19.

More news about Brilliant Acquisition Corporation.

10. Boxlight Corporation (BOXL) – -5.03%

Boxlight Corporation, an education technology company, develops, sells, and services interactive classroom solutions for the education market worldwide. The company provides a range of interactive classroom technology products primarily targeted at the K-12 education market. Its products include interactive projectors, interactive flat panel displays, interactive touch projectors, touchboards, and MimioTeach that could turn any whiteboard interactive; and accessory document cameras, teacher pads for remote control, and assessment systems. The company also offers MimioStudio Interactive Instructional Software that enables the creation, editing, and presentation of interactive instructional lessons and activities; MimioMobile, a software accessory for MimioStudio; Oktopus Instructional and Whiteboarding Software that enables the creation, editing, and presentation of interactive instructional lessons and activities; Notes+, a software accessory for use with Oktopus software; and GameZones and MimioInteract, which are multi-student interactive gaming software. In addition, it offers interactive touch tables and whiteboards; and peripherals and accessories, such as amplified speaker systems, mobile carts, installation accessories, and wall-mount accessories for interactive and standard projectors, and LED flat panels. Further, the company distributes interactive projectors and LED flat panels; and science, technology, engineering, and math data logging and robotics products. It has a strategic partnership with CareHawk for providing audio solutions for the education market. The company was formerly known as Logical Choice Corporation. Boxlight Corporation was incorporated in 2014 and is headquartered in Lawrenceville, Georgia.

NASDAQ ended the session with Boxlight Corporation dropping 5.03% to $0.53 on Friday while NASDAQ rose 2.05% to $11,697.80.

Earnings Per Share

As for profitability, Boxlight Corporation has a trailing twelve months EPS of $-0.14.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.17%.

Moving Average

Boxlight Corporation’s worth is way higher than its 50-day moving average of $0.42 and below its 200-day moving average of $0.57.

Yearly Top and Bottom Value

Boxlight Corporation’s stock is valued at $0.53 at 16:32 EST, way below its 52-week high of $1.42 and way higher than its 52-week low of $0.26.

More news about Boxlight Corporation.

Stay up to date with our winners and losers daily report